Acquired haemophilia A is an auto‐immune disease caused by an inhibitory antibody to
factor VIII. The pattern of bleeding varies but patients remain at risk of life threatening …

Acquired hemophilia A (AHA) is a rare disorder with an incidence of approximately 1 per
million/year with a high mortality rate of more than 20%. The disease occurs due to …

Acquired haemophilia A is an auto‐immune disease caused by an inhibitory antibody to
factor VIII. Patients with an acquired factor VIII inhibitor are at risk of life‐and limb …

Background: Hemophilia A (HA) and B (HB) are common bleeding disorders, Iran having the
ninth largest such population in the world. A considerable number of studies have been …

Recombinant activated factor VII (rFVIIa) was initially developed to overcome the limitations
of existing treatments for patients with congenital hemophilia and inhibitors. Clinical success …

Patients with congenital haemophilia with inhibitors or acquired haemophilia are at risk of
bleeding complications during surgery. In these patients, replacement therapy for the …

INTRODUCTION: In hemophilia, thrombin generation is significantly suppressed due to
decreased factor (F) X activation. Clinical studies and experiments with transgenic mice …

Objective To assess potential diagnostic and practice barriers to successful management of
massive postpartum hemorrhage (PPH), emphasizing recognition and management of …

Acquired hemophilia A (AHA) presents a significant bleeding risk. Management involves
bleeding control and immunosuppressive therapy (IST) to eliminate inhibitors. This study …

Interventions: The treatment requires a 2-pronged approach: treatment of the bleeding and
elimination of the inhibitor. Outcomes: After hemostatic agents were used and inhibitors …